Super enhancers: Pathogenic roles and potential therapeutic targets for acute myeloid leukemia (AML)

Ziyang Cao; Yi Shu; Jinxia Wang; Chunxia Wang; Tienan Feng; Li Yang; Jingbo Shao; Lin Zou

doi:10.1016/j.gendis.2022.01.006

您当前的位置：

首页 >

文章列表页 >

Super enhancers: Pathogenic roles and potential therapeutic targets for acute myeloid leukemia (AML)

更新时间：2022-11-09

- Super enhancers: Pathogenic roles and potential therapeutic targets for acute myeloid leukemia (AML)
- Genes & Diseases Vol. 9, Issue 6, (2022)
- 作者机构：
  
  1. Clinical Research Unit, Shanghai Children's Hospital, Shanghai Jiao Tong University,Shanghai,PR China,200062
  2. Institute of Pediatric Infection, Immunity, Critical Care Medicine, Shanghai Jiao Tong University School of Medicine,Shanghai,PR China,200062
  3. Center for Clinical Molecular Laboratory Medicine of Children's Hospital of Chongqing Medical University,Chongqing,PR China,400014
  4. Clinical Research Institute, Shanghai Jiao Tong University School of Medicine,Shanghai,PR China,200025
  5. Department of Hematology, The First Affiliated Hospital of Chongqing Medical University,Chongqing,PR China,400016
  6. Department of Hematology/Oncology, Shanghai Children's Hospital, Shanghai Jiao Tong University,Shanghai,PR China,200062
- 作者简介：
- 基金信息：
- DOI：10.1016/j.gendis.2022.01.006
  CLC：
- Published：2022，
  
  Published Online：1 November 2022，
扫描看全文
Ziyang Cao, Yi Shu, Jinxia Wang, et al. Super enhancers: Pathogenic roles and potential therapeutic targets for acute myeloid leukemia (AML). [J]. Genes & Diseases 9(6).(2022)
DOI：

Ziyang Cao, Yi Shu, Jinxia Wang, et al. Super enhancers: Pathogenic roles and potential therapeutic targets for acute myeloid leukemia (AML). [J]. Genes & Diseases 9(6).(2022) DOI： 10.1016/j.gendis.2022.01.006.

摘要

Abstract

ute myeloid leukemia (AML) is a malignant hematological tumor with disordered oncogenes/tumor suppressor genes and limited treatments. The potent anti-cancer effects of bromodomain and extra-terminal domain (BET) inhibitors

targeting the key component of super enhancers

in early clinical trials on AML patients

implies the critical role of super enhancers in AML. Here

we review the concept and characteristic of super enhancer

and then summarize the current researches about super enhancers in AML pathogenesis

diagnosis and classification

followed by illustrate the potential super enhancer-related targets and drugs

and propose the future directions of super enhancers in AML. This information provides integrated insight into the roles of super enhancers in this disease.

关键词

Keywords

AMLClassificationLeukemogenesisSuper enhancerTherapy targets

references

查看原文

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

RNA m⁶A reader YTHDF2 facilitates precursor miR-126 maturation to promote acute myeloid leukemia progression

Overcoming adaptive resistance in AML by synergistically targeting FOXO3A-GNG7-mTOR axis with FOXO3A inhibitor Gardenoside and rapamycin

Related Author

Keren Zhou

Zhijian Qian

David Ann

Chun-Wei Chen

Mark Boldin

Keith Leung

Kitty Wang

Xi Qin

Related Institution

Department of Systems Biology, Beckman Research Institute of City of Hope, Monrovia

Irell and Manella Graduate School of Biological Sciences, Beckman Research Institute of City of Hope, Duarte

School of Pharmacy, China Medical University

Tongji Hospital Affiliated to Tongji University, Frontier Science Center for Stem Cell Research, School of Life Sciences and Technology, Tongji University

Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine

⁰